Korean Drug Co., Ltd. (KOSDAQ:014570)
South Korea · Delayed Price · Currency is KRW 3,420.00
+15.00 (0.44%)
At close: Aug 24, 2026
Korean Drug Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 37,155 | 46,922 | 50,141 | 78,348 | 85,441 | 97,444 | |
Market Cap Growth | -26.70% | -6.42% | -36.00% | -8.30% | -12.32% | -13.30% |
Enterprise Value | 840 | 17,968 | 30,087 | 41,605 | 53,950 | 71,749 |
Last Close Price | 3405.00 | 4300.00 | 4405.30 | 6649.24 | 7098.22 | 7914.17 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.08 | 7.21 | 16.74 | - | 7.24 | 10.78 |
PS Ratio | 0.57 | 0.75 | 0.69 | 0.96 | 1.07 | 1.31 |
PB Ratio | 0.47 | 0.56 | 0.64 | 1.02 | 1.01 | 1.27 |
P/TBV Ratio | 0.47 | 0.57 | 0.64 | 1.02 | 1.01 | 1.27 |
P/FCF Ratio | 2.87 | 3.71 | 13.05 | - | - | 12.72 |
P/OCF Ratio | 2.81 | 3.58 | 10.30 | - | 14.45 | 11.07 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.01 | 0.29 | 0.41 | 0.51 | 0.68 | 0.96 |
EV/EBITDA Ratio | 0.09 | 2.02 | 4.87 | 4.91 | 3.43 | 5.63 |
EV/EBIT Ratio | 0.11 | 2.60 | 7.33 | 6.19 | 3.77 | 6.37 |
EV/FCF Ratio | 0.06 | 1.42 | 7.83 | - | - | 9.37 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Debt / FCF Ratio | 0.01 | 0.01 | 0.02 | - | - | 0.01 |
Net Debt / Equity Ratio | -0.46 | -0.36 | -0.24 | -0.22 | -0.31 | -0.36 |
Net Debt / EBITDA Ratio | -3.75 | -3.37 | -3.06 | -1.97 | -1.68 | -2.18 |
Net Debt / FCF Ratio | -2.80 | -2.37 | -4.92 | 7.88 | 146.19 | -3.63 |
Asset Turnover | 0.69 | 0.68 | 0.82 | 0.88 | 0.87 | 0.87 |
Inventory Turnover | 2.02 | 2.01 | 2.01 | 2.74 | 3.41 | 3.67 |
Quick Ratio | 3.40 | 6.41 | 5.81 | 4.52 | 7.81 | 5.51 |
Current Ratio | 4.39 | 8.33 | 8.73 | 6.41 | 9.80 | 6.82 |
Return on Equity (ROE) | 1.88% | 8.08% | 3.86% | -6.08% | 14.63% | 12.26% |
Return on Assets (ROA) | 5.09% | 4.72% | 2.87% | 4.56% | 9.78% | 8.19% |
Return on Invested Capital (ROIC) | 2.89% | 10.28% | 4.12% | -6.73% | 21.49% | 18.45% |
Return on Capital Employed (ROCE) | 9.40% | 8.00% | 5.00% | 8.40% | 16.50% | 14.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.99% | 13.88% | 5.97% | -6.28% | 13.82% | 9.28% |
FCF Yield | 34.88% | 26.97% | 7.66% | -2.71% | -0.21% | 7.86% |
Payout Ratio | 131.45% | 26.57% | 54.02% | - | 15.52% | 18.07% |
Buyback Yield / Dilution | - | -0.25% | -0.08% | 0.01% | 1.30% | -0.56% |